1. Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways 
Kurt Miller, Arnulf Stenzl, Bertrand Tombal 
European Urology Supplements 
Volume 8, Issue 9, Pages (September 2009)
DOI: /j.eursup
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
An overview of the physiologic balance between bone resorption and bone formation in normal healthy bone.
CFU-M=colony-forming unit-macrophage; RANKL=receptor activator of nuclear factor-κB ligand; RANK=receptor activator of nuclear factor-κB; OPG=osteoprotegerin.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
An overview of the vicious circle of bone destruction and tumour growth in osteolytic metastases.
RANKL=receptor activator of nuclear factor-κB ligand; RANK=receptor activator of nuclear factor-κB; OPG=osteoprotegerin.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
The incidence of skeletal-related events (SREs) during a 25-week treatment period among patients with bone metastases from prostate cancer after intravenous bisphosphonates who received denosumab or further bisphosphonate therapy in a multicentre, randomised, open-label, active-controlled phase 2 trial [27].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions